Roth MKM Reaffirms Their Buy Rating on Biofrontera (BFRI)

Tip Ranks
2025.11.14 13:57
portai
I'm PortAI, I can summarize articles.

Roth MKM's Jonathan Aschoff reaffirmed a Buy rating on Biofrontera (BFRI) with a $9.00 price target. Aschoff, who covers the Healthcare sector, has an average return of -18.3% and a 30.59% success rate. Benchmark Co.'s Bruce Jackson also issued a Buy rating, while TR reiterated a Hold rating on Biofrontera.

In a report released today, Jonathan Aschoff from Roth MKM maintained a Buy rating on Biofrontera, with a price target of $9.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Aschoff covers the Healthcare sector, focusing on stocks such as Biofrontera, GeoVax Labs, and Moleculin Biotech. According to TipRanks, Aschoff has an average return of -18.3% and a 30.59% success rate on recommended stocks.

In addition to Roth MKM, Biofrontera also received a Buy from Benchmark Co.’s Bruce Jackson in a report issued today. However, yesterday, TR | OpenAI – 4o reiterated a Hold rating on Biofrontera (NASDAQ: BFRI).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.